Acta Microbiologica et Immunologica Hungarica, 60 (4), pp. 411–422 (2013) DOI: 10.1556/AMicr.60.2013.4.3
BACTERIOPHAGE THERAPY AGAINST STAPHYLOCOCCI JÓZSEF KLEM1, DÓRA DÖMÖTÖR2, GYÖRGY SCHNEIDER3, TAMÁS KOVÁCS2, ANDRÁS TÓTH1,4 and GÁBOR RÁKHELY1,4* 1
Department of Biotechnology, University of Szeged, Szeged, Hungary Department of Biotechnology, Enviroinvest Corporation, Pécs, Hungary 3 Institute of Medical Microbiology and Immunology, University of Pécs, Pécs, Hungary 4 Institute of Biophysics, Biological Research Center, Hungarian Academy of Sciences, Szeged, Hungary 2
(Received: 25 February 2013; accepted: 23 May 2013)
The emergence of the multi-drug-resistant Staphylococcus aureus strains has prompted interest in alternatives to conventional drugs. Among the possible options one of the most promising is the therapeutic use of bacteriophages. Over the recent decades, increasing amount of literature has validated the use of bacteriophages for therapy and prophylaxis against drug-resistant staphylococci. This work attempts to review the current knowledge on bacteriophages and their usages for treatment of staphylococcal diseases. Keywords: Staphylococcus, phage, bacteriophage therapy, alternative antimicrobials
Introduction Staphylococcus aureus being a commensal bacterium of humans and other vertebrates is able to bypass all barriers of the host defense system as it possesses a wide spectrum of virulence factors [1]. S. aureus initially causes local infections which can develop into systematic infections in later stages such as bacteremia and sepsis [2]. Local infections are associated either with skin and soft tissue damage such as the folliculitis, cellulitis, abscesses and wound infections [3, 4] or with deep infections such as myositis [5], osteomyelitis [6], peri- and endocarditis [7], * Corresponding author; E-mail: [email protected]
1217-8950/$20.00 © 2013 Akadémiai Kiadó, Budapest
BACTERIOPHAGE THERAPY AGAINST STAPHYLOCOCCI JÓZSEF KLEM1, DÓRA DÖMÖTÖR2, GYÖRGY SCHNEIDER3, TAMÁS KOVÁCS2, ANDRÁS TÓTH1,4 and GÁBOR RÁKHELY1,4* 1
Department of Biotechnology, University of Szeged, Szeged, Hungary Department of Biotechnology, Enviroinvest Corporation, Pécs, Hungary 3 Institute of Medical Microbiology and Immunology, University of Pécs, Pécs, Hungary 4 Institute of Biophysics, Biological Research Center, Hungarian Academy of Sciences, Szeged, Hungary 2
(Received: 25 February 2013; accepted: 23 May 2013)
The emergence of the multi-drug-resistant Staphylococcus aureus strains has prompted interest in alternatives to conventional drugs. Among the possible options one of the most promising is the therapeutic use of bacteriophages. Over the recent decades, increasing amount of literature has validated the use of bacteriophages for therapy and prophylaxis against drug-resistant staphylococci. This work attempts to review the current knowledge on bacteriophages and their usages for treatment of staphylococcal diseases. Keywords: Staphylococcus, phage, bacteriophage therapy, alternative antimicrobials
Introduction Staphylococcus aureus being a commensal bacterium of humans and other vertebrates is able to bypass all barriers of the host defense system as it possesses a wide spectrum of virulence factors [1]. S. aureus initially causes local infections which can develop into systematic infections in later stages such as bacteremia and sepsis [2]. Local infections are associated either with skin and soft tissue damage such as the folliculitis, cellulitis, abscesses and wound infections [3, 4] or with deep infections such as myositis [5], osteomyelitis [6], peri- and endocarditis [7], * Corresponding author; E-mail: [email protected]
1217-8950/$20.00 © 2013 Akadémiai Kiadó, Budapest
